PensionDanmark Pensionsforsikringsaktieselskab Purchases 1,800 Shares of West Pharmaceutical Services, Inc. $WST

PensionDanmark Pensionsforsikringsaktieselskab boosted its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 14.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 14,260 shares of the medical instruments supplier’s stock after buying an additional 1,800 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in West Pharmaceutical Services were worth $5,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealth Alliance LLC lifted its holdings in shares of West Pharmaceutical Services by 3.8% during the first quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock worth $237,000 after buying an additional 35 shares in the last quarter. IFM Investors Pty Ltd grew its stake in shares of West Pharmaceutical Services by 0.3% in the first quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock valued at $3,452,000 after acquiring an additional 43 shares in the last quarter. Compound Planning Inc. increased its position in West Pharmaceutical Services by 3.6% during the first quarter. Compound Planning Inc. now owns 1,224 shares of the medical instruments supplier’s stock worth $307,000 after acquiring an additional 43 shares during the period. Aptus Capital Advisors LLC raised its stake in West Pharmaceutical Services by 5.5% in the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock worth $249,000 after purchasing an additional 47 shares in the last quarter. Finally, Cornerstone Planning Group LLC raised its stake in West Pharmaceutical Services by 90.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 50 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on WST. TD Cowen restated a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Morgan Stanley boosted their price target on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Wolfe Research started coverage on West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 price target on the stock. Citigroup raised their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $310.00 to $400.00 in a research report on Tuesday, June 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $353.61 on Monday. The firm has a 50 day moving average of $342.97 and a 200-day moving average of $292.48. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $24.89 billion, a PE ratio of 45.28, a PEG ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. During the same period last year, the firm posted $1.84 earnings per share. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities research analysts predict that West Pharmaceutical Services, Inc. will post 8.94 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were paid a $0.22 dividend. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.